



**World Health
Organization**

Draft agenda
Meeting of the Immunization Strategic Advisory Group of Experts
10-11 April 2006
Centre International de Conférences de Geneve,
17 rue de Varembe, Geneva

Monday 10 April

Time	Session	Purpose of session, target outcomes and questions for SAGE	
08:30	Welcome - introduction		15mn
08:45	Report from Director of Department of Immunization, Vaccines and Biologicals Presentation JM. Okwo-Bele 10mn Discussion 10 mn	FOR DISCUSSION - Report to SAGE on achievement of previous recommendations - Feed-back on SAGE restructuring	20mn
09:05	Analysis of national budget lines for vaccines and financing Vaccine financing and budget lines - what do we know and what are the trends? 10mn P. Lydon Discussion 15mn	FOR INFORMATION	25mn
09:30	Priorities, major policy and implementation issues: reports from AFRO, EMRO, and SEARO with emphasis on how regions will move towards GIVS	FOR DISCUSSION - Provide SAGE with background	2hr

	implementation (ctd) AFRO 20 mn D. Nshimirimana EMRO 20 mn S. Youssouf SEARO 20 mn P. Namgyal Discussion 60 mn	information in defining global immunization priorities	
10:30	Coffee Break	Break	30mn
11:00	Priorities, major policy and implementation issues (ctd)		
12:00	Intermittent preventive treatment of infants (IPTi) for malaria co-administered with immunization Intermittent preventive treatment of infants (IPTi) for malaria co-administered with immunization 20mn J. Crawley Discussion 25mn	FOR DISCUSSION <ul style="list-style-type: none"> - Discussion on the proposed policy development process - Help plan the November meeting when SAGE will formally be asked to review the proposed policy 	45mn
12:45	Lunch break	Break	1hr
13:45	Japanese encephalitis vaccination JE surveillance and disease burden 15mn Z-Y Xu The vaccine situation 15mn I. Kurane and J. Jacobson Situation analysis on current immunization strategies 15mn J. Jacobson Specific country initiatives 10 mn P. Namgyal Discussion 65mn	FOR DECISION <ul style="list-style-type: none"> - Inform SAGE on existing strategies and policies to immunize against JE - Provide advice to WHO regions on considerations for vaccine introduction, particularly with respect to immunization strategies and surveillance - Provide recommendation to WHO for the revision of the JE vaccine position paper 	2hrs

15:45	Coffee break	Break	30mn
16:15	Mumps vaccination WHO vaccine position paper on mumps and report form GACVS 10 mn H. Bashour Challenges with control of mumps in EMR and outcome of the mumps consultation 15 mn F. Mahoney Review of recent literature D Brown 10 mn Availability of mumps vaccine strains and vaccine formulations P. Carrasco 10 mn Discussion 40 mn	FOR DISCUSSION - Clarify advice on vaccination strategies - Is there a need to revise the WHO mumps vaccine position paper?	1hr 15mn
17:30	Update on pneumococcal sub-group Presentation 10mn A. Reingold Discussion 20mn	FOR INFORMATION - Update SAGE on the progress with the development of the pneumococcal position statement - Provide inputs/proposed modifications to the scope of the proposed position statement	30mn
18:00	Cocktail		

Tuesday 11 April

08:30	<p>Update on move towards optimization of immunization schedules and specific discussion on tetanus immunization</p> <p>Update on the "Immunological basis for tetanus immunization" module 25mn R. Borrow Discussion 25mn</p> <p>WHO position paper on tetanus 20mn G. Peter Discussion 20mn</p> <p>Approach to reviewing other components of the immunization schedule 10mn MP Kieny Discussion 20mn</p>	<p>FOR DECISION</p> <ul style="list-style-type: none"> - Recommendations regarding booster doses of tetanus toxoid - Suggestions for improvement and endorsement of WHO position paper on tetanus toxoid - -Agreement on process to review other components of the immunization schedule - Establishment of SAGE sub-group 	2hrs
10:30	Coffee break	Break	30mn
11:00	<p>Report on influenza vaccine</p> <ul style="list-style-type: none"> - Influenza pandemic vaccine development: current status development of global action plan to shorten pandemic vaccine gap 20 mn K. Stöhr - IVB and EPR workplans in influenza vaccine development (with particular emphasis relating to SAGE recommendations) 10 mn D. Lavanchy and K. Stöhr - Regulatory preparedness for influenza pandemics: global status and WHO activities 10 mn D. Wood 	<p>FOR INFORMATION</p> <ul style="list-style-type: none"> - Provide overview on global activities in influenza pandemic vaccine development - Inform members on WHO wide activities in influenza vaccine development and upcoming meetings 	1hr

	Discussion 20 mn		
12:00	Report on Progress with implementation of immunization safety related activities-Follow-up of recommendations from the steering committee of the Immunization Safety Priority Project Presentation 15 mn D. Wood Discussion 10 mn	FOR INFORMATION	25mn
12:25	Lunch break	Break	1hr
13:25	Reports from other advisory committees in immunization Global Advisory Committee on Vaccine Safety Presentation 10 mn S. Salmaso Expert Committee on Biological Standardization Presentation 10 mn R. Dobbelaer Advisory Committee on Polio Eradication: update on deliberations Presentation 10 mn S. Bino Total discussion time for 3 committee reports 15 mn	FOR INFORMATION	45mn
14:10	Measles mortality reduction: an update and planning for future discussions on the next global measles goals Activities and progress towards global mortality reduction goal 10 mn E. Hoekstra Proposal for the process to establish the next global goal 10 mn J. Santos	FOR DISCUSSION <ul style="list-style-type: none"> - Provide an update on activities and progress towards the mortality reduction goal - Discuss the option of relying solely on the GIVS measles mortality reduction goal or define the process to establish 	1hr 15mn

	<p>Discussion 20mn</p> <p>Lessons from recent measles outbreaks and recommendations from AFRO measles TAG on strategies to maintain population immunity 15mn D. Nshimirimana</p> <p>Discussion 20mn</p>	<p>the next global goal for measles control</p> <ul style="list-style-type: none"> - Define the next steps to enable the fine tuning of strategies for measles mortality reduction (e.g., when to introduce a routine 2nd dose? When to increase the age of 1st dose from 9 to 12 months? And what is the appropriate interval between follow-up SIAs?) 	
15:25	Coffee break	Break	30mn
15:55	<p>Surveillance Framework</p> <p>Outline of the Global Vaccine Preventable Surveillance and Monitoring Framework 15mn R. Eggers</p> <p>Discussion 15mn</p>	<p>FOR DISCUSSION</p> <ul style="list-style-type: none"> - To inform SAGE of the process to formulate a new Global VPD Surveillance and Monitoring Framework to provide strategic direction in VPD surveillance and monitoring for the coming five years, as an additional document to complement GIVS 	30mn
16:25	Closing		35mn
17:00	End of meeting		